ライフサイエンスコーパス: levothyroxine

1 is thyroid hormone replacement therapy with levothyroxine.

2 d levothyroxine product vs switching generic levothyroxine.

3 iteria to open-label infusion of intravenous levothyroxine (30 mug per hour for a minimum of 12 hours

4 women to receive either 50 mug once daily of levothyroxine (476 women) or placebo (476 women) before

5 tment with thyroid extract was superseded by levothyroxine, a synthetic L form of tetraiodothyronine.

6 identify precisely the timing and amount of levothyroxine adjustment required during pregnancy.

7 hylprednisolone alone or in combination with levothyroxine allowed for significant reduction in vasop

8 Levothyroxine alone offered no advantage in reducing vas

9 Compared with levothyroxine alone, treatment of primary hypothyroidism

10 15 score at 12 months was 1.39 (2.13) in the levothyroxine and 1.07 (1.67) in the placebo group with

11 transplanted from donors assigned to receive levothyroxine and 213 hearts (95.5%) transplanted from d

12 total of 427 participants (211 randomized to levothyroxine and 216 to placebo) were analyzed.

13 oral bexarotene 400 mg/m2/d plus concomitant levothyroxine and a lipid-lowering agent.

14 However, neither studies combining levothyroxine and liothyronine (the synthetic form of tr

15 ver-treatment with thyroid hormones (such as levothyroxine and liothyronine).

16 r, inverse associations of hydroxocobalamin, levothyroxine and mometasone were unexpected and needs f

17 (36.7%) cardiovascular adverse events in the levothyroxine and placebo groups, respectively.

18 showed a significant difference between the levothyroxine and placebo treatment groups.

19 Treatment with levothyroxine and radioiodine contribute alternative car

20 ould inhibit the formation of (131)I-labeled levothyroxine and triiodothyronine and thereby reduce th

21 iation was unmitigated by gestational use of levothyroxine and was unexplained by maternal gestationa

22 profiling of an amino group containing drug (levothyroxine) and its metabolites in human plasma, base

23 tal of 368 patients were assigned to receive levothyroxine (at a starting dose of 50 mug daily, or 25

24 acute myocardial infarction, treatment with levothyroxine, compared with placebo, did not significan

25 h subclinical hypothyroidism, treatment with levothyroxine, compared with placebo, was not significan

26 Small trials indicate that the use of levothyroxine could reduce the incidence of such adverse

27 yrotropin levels should be monitored and the levothyroxine dose adjusted accordingly.

28 oidism, and can be managed by increasing the levothyroxine dose by 30% when pregnancy is confirmed.

29 hat women with hypothyroidism increase their levothyroxine dose by approximately 30 percent as soon a

30 en with hypothyroidism should increase their levothyroxine dose during pregnancy, biochemical hypothy

31 During gestation, an increase in levothyroxine dose is required in more than 50% of women

32 hese patients, 56.3% [8905] received a daily levothyroxine dose of 50 mug or less.

33 yroid function was assessed monthly, and the levothyroxine dose was adjusted to attain a normal thyro

34 An increase in the levothyroxine dose was necessary during 17 pregnancies.

35 ation therapy (n = 23), in which their usual levothyroxine dose was reduced by 50 micro g/d and subst

36 at least a 6-month history of treatment with levothyroxine for primary hypothyroidism.

37 These findings do not support routine use of levothyroxine for treatment of subclinical hypothyroidis

38 A total of 266 of 470 women in the levothyroxine group (56.6%) and 274 of 470 women in the

39 , as compared with 3.63 mIU per liter in the levothyroxine group (P<0.001), at a median dose of 50 mu

40 t occurred in 33 participants (29.5%) in the levothyroxine group (the most common adverse event was c

41 ean (SD) GDS-15 score was 1.26 (1.85) in the levothyroxine group and 0.96 (1.58) in the placebo group

42 transplanted from 230 donors (54.9%) in the levothyroxine group and 223 (53.2%) in the saline group

43 erse events occurred in 5.9% of women in the levothyroxine group and 3.8% in the placebo group (P = 0

44 rth rate was 37.4% (176 of 470 women) in the levothyroxine group and 37.9% (178 of 470 women) in the

45 included in the primary analysis: 419 in the levothyroxine group and 419 in the saline group.

46 an IQ score was 94 (95% CI, 91 to 95) in the levothyroxine group and 91 (95% CI, 89 to 93) in the pla

47 % confidence interval [CI], 94 to 99) in the levothyroxine group and 94 (95% CI, 92 to 96) in the pla

48 ks was 51.3% and 53.8%, respectively, in the levothyroxine group compared with 54.0% and 56.1%, respe

49 d Combo groups and significantly less in the levothyroxine group compared with controls.

50 hypertension and tachycardia occurred in the levothyroxine group than in the saline group.

51 21.7 at baseline to 19.3 at 12 months in the levothyroxine group vs from 19.8 at baseline to 17.4 at

52 25.5 at baseline to 28.2 at 12 months in the levothyroxine group vs from 25.1 at baseline to 28.7 at

53 3 in the placebo group and 0.2+/-14.4 in the levothyroxine group; between-group difference, 0.0; 95%

54 after 12 months to 3.83 (2.29) mIU/L in the levothyroxine group; in the placebo group, it decreased

55 and a substantial proportion of patients on levothyroxine have thyroid-stimulating hormone concentra

56 = 199) were randomized to receive high-dose levothyroxine, high-dose methylprednisolone, both (Combo

57 thetic triiodothyronine, or liothyronine, to levothyroxine improves the symptoms of hypothyroidism de

58 The use of levothyroxine in euthyroid women with thyroid peroxidase

59 s do not support the practice of prescribing levothyroxine in patients with subclinical hypothyroidis

60 re Advantage enrollees to analyze the use of levothyroxine in the US over time.

61 first trimester progesterone administration, levothyroxine in women with subclinical hypothyroidism,

62 ain-dead potential heart donors, intravenous levothyroxine infusion did not result in significantly m

63 Levothyroxine is the first-line treatment to normalize t

64 ndex (BMI) of 28.5 but is otherwise healthy; levothyroxine is the only prescription medication she ta

65 Intravenous levothyroxine is widely used in donor care, on the basis

66 reatment for patients with hypothyroidism is levothyroxine (L-T4) along with normalization of serum t

67 Adding supraphysiologic doses of levothyroxine (L-T4) to standard treatment for bipolar d

68 Levothyroxine (LT4) is a form of thyroid hormone used to

69 Levothyroxine (LT4) is the mainstay of treatment and is

70 that T3 deficiency may be unavoidable during levothyroxine (LT4) therapy.

71 ectomy and subsequent (131)I treatment after levothyroxine (LT4) withdrawal between January 2022 and

72 ciation reflected the general consensus that levothyroxine (LT4), adjusted to maintain a normal thyro

73 A total of 15 829 patients filled generic levothyroxine (mean [SD] age, 58.9 [14.6] years; 73.4% [

74 - 2.6, 10.9 +/- 2.6, and 7.1 +/- 2.6 for the levothyroxine, methylprednisolone, Combo, and Control gr

75 Levothyroxine monotherapy is the standard treatment for

76 rticipants were randomly assigned to receive levothyroxine (n = 112; 52 participants from the first t

77 Patients received either their usual dose of levothyroxine (n = 23) or combination therapy (n = 23),

78 Previous trials on the effect of levothyroxine on depressive symptom scores in patients w

79 SU can improve in response to treatment with levothyroxine or other thyroid drugs (strong evidence).

80 Randomization to either levothyroxine or placebo.

81 ons, women were randomly assigned to receive levothyroxine or placebo.

82 screening group were assigned to 150 mug of levothyroxine per day.

83 t of primary hypothyroidism with combination levothyroxine plus liothyronine demonstrated no benefici

84 The 4 generic and brand-name levothyroxine preparations studied are different but are

85 sults are equally applicable to all existing levothyroxine preparations.

86 ion, and 2780 (17.6%) switched among generic levothyroxine preparations.

87 older were included if they filled a generic levothyroxine prescription between January 1, 2008, and

88 that has been treated with a stable dose of levothyroxine presents to her primary care provider with

89 inary outcome of continuing the same sourced levothyroxine product vs switching generic levothyroxine

90 the same product or switching among generic levothyroxine products (index date).

91 All patients received each of the 4 levothyroxine products for 6-week periods in the same do

92 in TSH level associated with switching among levothyroxine products sourced from different manufactur

93 ggest that switching among different generic levothyroxine products was not associated with clinicall

94 We aimed to determine whether levothyroxine provided clinical benefits in older person

95 Levothyroxine provided no apparent benefits in older per

96 truction or removal, necessitating life-long levothyroxine replacement.

97 The mean levothyroxine requirement increased 47 percent during th

98 Levothyroxine requirements increase as early as the fift

99 hypothyroidism is diagnosed, treatment with levothyroxine should be started to achieve serum TSH con

100 Switching among generic levothyroxine sodium products made by different manufact

101 and chemically euthyroid and were receiving levothyroxine sodium, 0.1 or 0.15 mg.

102 Levothyroxine substitution improves, but does not always

103 esuscitation, specifically administration of levothyroxine (T4) and methylprednisolone (steroid, i.e.

104 de thyroid hormone (triiodothyronine [T3] or levothyroxine [T4]), corticosteroids, antidiuretic hormo

105 hat depressive symptoms did not differ after levothyroxine therapy compared with placebo after 12 mon

106 results do not provide evidence in favor of levothyroxine therapy in older persons with subclinical

107 However, levothyroxine therapy may be associated with iatrogenic

108 large randomized trials showing benefit from levothyroxine therapy, the rationale for treatment is ba

109 ne treatment for hypothyroidism is synthetic levothyroxine to normalize thyrotropin levels.

110 The use of levothyroxine to treat subclinical hypothyroidism is con

111 Levothyroxine treatment (n = 46) commencing at 25 ug tit

112 Ongoing symptoms despite levothyroxine treatment has led to some patients using l

113 It is unknown whether levothyroxine treatment of women who are identified as h

114 It is unclear whether levothyroxine treatment provides clinically important be

115 The median gestational age at the start of levothyroxine treatment was 13 weeks 3 days; treatment w

116 progeny, yet clinical trials indicated that levothyroxine treatment was ineffective in preventing ne

117 cebo-controlled trial to investigate whether levothyroxine treatment would increase live-birth rates

118 d be performed 6 to 8 weeks after initiating levothyroxine treatment, or when changing the dose, and

119 ulating hormone elevations will benefit from levothyroxine treatment.

120 sive symptoms is often a reason for starting levothyroxine treatment.

121 In addition, levothyroxine use was determined in age- and sex-matched

122 id function status, polysomnography results, levothyroxine use, and clinical signs and symptoms in 33

123 djusted between-group difference of 0.15 for levothyroxine vs placebo (95% CI, -0.15 to 0.46; P = .33

124 The dose of levothyroxine was increased to maintain the thyrotropin

125 purinol, mometasone, metformin, simvastatin, levothyroxine were inversely associated.

126 No beneficial effects of levothyroxine were seen on secondary-outcome measures.

127 clear; although, treatment with low doses of levothyroxine, which is usually used to treat hypothyroi

128 eta-analysis (N = 278) on the association of levothyroxine with depressive symptoms was updated to in